Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
Amgen (NASDAQ: AMGN) today announced it will discontinue Future development of AMG 513. A Phase 1 study of AMG 513 in adults living with obesity will remain ongoing to follow enrolled participants through completion of
Amgen stopped making plans for a new obesity medicine but is finishing the safety test it already started with patients. This tells us the company found something worth studying more before deciding if it's ready for people to use.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.